Clinical Trials in South Korea / NCT05463224
Active, not recruiting
Phase 2
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
NCT05463224 · tracked via the Priya Life Science South Korea tracker
Condition(s) studied
NSCLC
Investigational drug(s) / intervention(s)
Lazertinib group
Lazertinib group: Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)
Study summary
The primary objective is to evaluate the efficacy/safety of lazertinib and to explore the resistance mechanism of lazertinib as first-line in patients with NSCLC harboring activating EGFR mutations.
Eligibility
Inclusion Criteria:
* Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer which is not amenable to treatment with a curative aim (e.g. surgery or radiation). Patients who underwent curative intent surgery or definitive CRT and experience recurrence after 6 months are eligible.
* Stage IIIC or IV by AJCC 8th edition
* Confirmed EGFR mutations (exon 19 deletion, L858R)(The result from both cell-free DNA or tissue-based DNA from the local test is allowed.)
* Age of 19 or more.
* Performance status of Eastern Cooperative Oncology Group 0 to 2.
* Expected minimum life expectancy of 12 weeks
* Adequate organ function.
* Available to provide the adequate tissue and blood for the genomic tests- At least 15 unstained slide and 20 cc of blood at baseline (mandatory) and disease progression.
* Agreed to perform re-biopsy at the timepoint of disease progression.
* At least two weeks after the chemotherapy
* Female subjects must either be of non-reproductive potential
* Subject willing and able to comply with the protocol
* Signed written informed consent
Exclusion Criteria:
* Previously treatment with any kind of EGFR TKI (Previously chemotherapy treated patients is allowed)
* Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug. (allowed for participation if investigator decided that previous malignancy is cured and not need for any additional treatment)
* Uncontrolled central nervous system metastases- patient with asymptomatic brain metastases or CNS symptom manageable with TKI and evaluated by investigator can be enrolled.
* Spinal cord compression, leptomeningeal carcinomatosis
* Uncontrolled systemic illness, including uncontrolled hypertension, active bleeding, or active infection
* Radiotherapy with a wide field of radiation within 2 weeks or radiotherapy with a limited field of radiation (localized radiotherapy or gamma knife surgery) for palliation within 1 week
* Any unresolved toxicities from prior therapy, greater than CTCAE grade 1
* Mean QT interval corrected for heart rate (QTc) ≥ 470 ms
* No measurable lesion
* Unable to swallow the product due to refractory nausea, vomiting or chornic gastrointestinal disease.
Primary outcome measure(s)
- progression-free survival — through study completion, an average of 18.0 month
C1D1 until the date of objective disease progression or death - Resistance mechanism analysis — Screening, Discontiunuation Visit
The mutation profile of baseline and at the timepoint of resistance will be evaluated using tissue and cfDNA
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Samsung Medical Center | Seoul | Gangnamgu |
More Sehhoon Park trials in South Korea
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05463224 on ClinicalTrials.gov ↗ ← All trials in South Korea